Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma

Lignende værker

• Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
  af: Subbiah, V., et al.
  Udgivet: (2021)
• P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer
  af: Katayama, Ryohei, et al.
  Udgivet: (2015)
• Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
  af: Kitadai R, et al.
  Udgivet: (2018-12-01)
• Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
  af: Kitadai, Rui, et al.
  Udgivet: (2018)
• Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
  af: Nishio, Makoto, et al.
  Udgivet: (2015)